Neurosense Therapeutics Ltd Total Liabilities
Neurosense Therapeutics Ltd total liabilities. Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has total liabilities worth $2.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NRSN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neurosense Therapeutics Ltd (2019–2025)
Total liabilities of Neurosense Therapeutics Ltd from 2019 to 2025. This chart illustrates how Neurosense Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Neurosense Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inocycle Technology Tbk PT
JK:INOV
|
Indonesia | Rp682.16 Billion |
|
ABERA BIOSCIENCE AB
F:8WK
|
Germany | €7.57 Million |
|
Taiwan Thick-Film Ind
TWO:6246
|
Taiwan | NT$887.83 Million |
|
Pelikan International Corp
KLSE:5231
|
Malaysia | RM64.67 Million |
|
FIREBIRD METALS LTD
F:7Y2
|
Germany | €245.59K |
|
Raptis Group Ltd
AU:RPG
|
Australia | AU$62.52K |
|
Freeport Resources Inc
V:FRI
|
Canada | CA$93.15K |
|
Peak Processing Limited
AU:PKP
|
Australia | AU$18.75 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Neurosense Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Neurosense Therapeutics Ltd asset portfolio.
Liquidity & Leverage Metrics
Neurosense Therapeutics Ltd Total Liabilities Ratios Explained
Neurosense Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurosense Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual total liabilities of Neurosense Therapeutics Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.59 Million | +29.92% |
| 2024-12-31 | $1.99 Million | -59.71% |
| 2023-12-31 | $4.94 Million | +136.44% |
| 2022-12-31 | $2.09 Million | -13.77% |
| 2021-12-31 | $2.42 Million | +1920.83% |
| 2020-12-31 | $120.00K | +224.32% |
| 2019-12-31 | $37.00K | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more